NASDAQ · ACCD
Healthcare · Medical - Healthcare Information Services
$7.02
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 3:46 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ACCD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ACCD.
ACCD research
Company profile and research snapshot.
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 12, 2025 | Stephens & Co. | Equal-Weight | — |
| Jan 9, 2025 | Stifel | Hold | — |
| Jan 9, 2025 | Raymond James | Market Perform | — |
| Jan 8, 2025 | Canaccord Genuity | Hold | — |
| Jan 8, 2025 | Leerink Partners | Market Perform | — |
No generated briefing is available yet.
Benzinga · Feb 24, 2025
Transcarent and Accolade announced the expiration of the Hart-Scott-Rodino waiting period for their pending merger, bringing them one step closer to completing the transaction in the second quarter of 2025.
Benzinga · Jan 8, 2025
Transcarent agreed to acquire Accolade Inc for $621 million, a 110% premium over its previous closing price. The merger combines Transcarent's AI-powered care offerings with Accolade's healthcare platform and expertise in advocacy and primary care.
Benzinga · Jan 8, 2025
Transcarent, a healthcare platform, announced it will acquire Accolade, a leader in health advocacy and expert medical opinions, for $7.03 per share in cash. The combined company aims to provide a more personalized and engaging healthcare experience for members.
GlobeNewswire Inc. · Nov 13, 2024
Accolade, Inc. announced that it will be presenting at several upcoming investor events, including the Stephens Annual Investment Conference, the CG MedTech, Diagnostics and Digital Health & Services Forum, and the Piper Sandler 36th Annual Healthcare Conference.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACCD.
No results
No recent SID articles mention ACCD.
